Motinorm

Quick links to important sections

Motinorm

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Motinorm

Property Description
Active Ingredient Domperidone
Pharmacological Class Dopamine Antagonist, Gastroprokinetic Agent, Antiemetic
Forms Tablets (including ODTs), Oral Suspension, Oral Drops, Suppositories
Common Use Relief of Nausea, Vomiting, and Upper Gastrointestinal Discomfort
Origin Synthetic organic compound (Benzimidazole derivative)

What Type of Medicine is Motinorm (Domperidone)?

Motinorm is a synthetic, single-ingredient medicinal preparation derived from the compound Domperidone, which belongs to the chemical class of Benzimidazole derivatives. The medicine is pharmacologically classified as a Dopamine Antagonist, primarily recognized for its function as a Gastroprokinetic Agent and an Antiemetic. The mechanism of Domperidone involves enhancing digestive system function without exhibiting the same level of central nervous system involvement as certain older antiemetics.

Domperidone is noted for being peripherally selective, a key differentiating factor. This means the active substance predominantly blocks dopamine receptors located outside of the central nervous system, concentrating its effect on the upper gastrointestinal tract and the chemoreceptor trigger zone that initiates the vomiting reflex.

Composition and Available Pharmaceutical Forms

The sole active component in Motinorm is Domperidone. The medication is available in multiple Dosage form(s) to suit diverse therapeutic needs, facilitating both Oral administration (using standard Tablets, film-coated tablets, or liquid formats like Oral suspension and Oral drops) and, in some formulations, Rectal administration via Suppositories. The availability of liquid formats and orally disintegrating tablets is beneficial for patient groups such as adolescents or those experiencing acute nausea where swallowing is difficult.

General Purpose and Primary Action

Motinorm's general purpose is to restore and normalize the movement of the upper digestive system, providing relief from discomfort associated with slow digestion. Its Gastroprokinetic properties function by accelerating gastric emptying and enhancing gastroduodenal coordination. This physical action, combined with the receptor-blocking effect in the chemoreceptor trigger zone, provides the overall benefit of helping to control the feeling and involuntary reflex associated with Nausea and Vomiting.

Regulatory References

  1. Domperidone - Drugs and Lactation Database (LactMed)

What side effects are possible with Motinorm?

Motinorm (Domperidone) is associated with specific safety concerns that have led to restrictions on its use by regulatory authorities, primarily related to potential cardiac adverse reactions.

Serious Safety Concerns and Restrictions

The most significant risk is a small increased chance of serious ventricular arrhythmias, including QTc interval prolongation, Torsade de Pointes, and sudden cardiac death. This risk is higher with doses exceeding 30 mg daily, in patients over 60 years of age, and when used for prolonged periods. For this reason, official guidance strictly limits use to the lowest effective dose for the shortest duration, typically not exceeding one week.

Contraindications prohibit the use of Motinorm in patients with:

  • Pre-existing conditions that prolong cardiac conduction (like a prolonged QTc interval).
  • Underlying heart diseases, such as congestive heart failure.
  • Moderate to severe hepatic (liver) impairment.
  • Significant electrolyte disturbances.
  • Concomitant use with specific medications known to prolong the QT interval or potent CYP3A4 inhibitors (which increase Motinorm blood levels).

Common and Other Adverse Reactions

Adverse reactions commonly reported (affecting up to 1 in 100 people) include dry mouth and headache. Other effects may involve the endocrine system due to elevated prolactin levels (hyperprolactinemia), which can manifest as gynecomastia (breast enlargement in men) or galactorrhea (unusual milk production) and menstrual irregularities in women. Though rare, central nervous system effects such as extrapyramidal symptoms have been reported, particularly in children or when high doses are used. Sudden discontinuation from long-term, high-dose therapy (often for off-label use) has been associated with reports of neuropsychiatric withdrawal events like anxiety and depression.

Overdose and Emergency Response

Overdose Manifestations and When to Seek Help

Official regulatory documentation describes that an overdose of Motinorm (Domperidone) is associated with documented neurological manifestations. These presentations include somnolence (drowsiness), disorientation, and agitation. Overdosage may also result in extrapyramidal reactions, which are characterized by uncontrolled movements, or the occurrence of convulsions. These specific symptoms are reported especially in infants and children.

The regulatory profile emphasizes the potential for a severe cardiovascular risk: QTc interval prolongation, which carries a risk of serious ventricular arrhythmias and sudden cardiac death. Medical attention must be sought straight away if an overdose is suspected or if symptoms associated with cardiac arrhythmia (e.g., dizziness, fainting) occur.

Due to the absence of a specific antidote, immediate standard symptomatic treatment and close medical observation are required. Supportive therapy may include the administration of activated charcoal or gastric lavage if performed within one hour of ingestion. To manage the primary severe risk, Electrocardiogram (ECG) monitoring should be undertaken. This continuous monitoring is crucial for detecting and managing the possibility of QTc interval prolongation, which is the chief constraint defined within the overdose section of the official labeling.

Therapeutic Uses of Motinorm

Quick Facts: Motinorm

  • Main Therapeutic Domain: Management of nausea and vomiting.
  • Additional Use: Addresses symptoms associated with slow movement of the stomach and upper intestine (gastroparesis), such as the sensation of fullness and bloating.
  • Action: Works to increase the transit of food through the digestive tract.

Motinorm is prescribed for the symptomatic management of nausea and vomiting. It operates by affecting the digestive system to enhance the movement of the stomach and upper intestines, which assists in facilitating the transit of food. This prokinetic action can help provide relief from symptoms associated with a reduction in the normal movement of the digestive tract, such as a constant feeling of being full (satiety) or abdominal bloating.

In some countries, Motinorm's active agent is also specifically used to address the chronic gastrointestinal condition known as gastroparesis (delayed gastric emptying). Treatment in this area is intended to mitigate associated upper gastrointestinal symptoms including stomach discomfort, fullness, and sickness. Patients should always follow the dosage and duration guidelines provided by a healthcare professional, as serious health warnings exist concerning its use.

Eligibility and Restrictions for Use

Motinorm (Domperidone) eligibility is strictly defined by regulatory authorities, outlining specific patient populations who are allowed to use the medicine and those who must not use it.

Contraindicated Populations (Must Not Use)

Official labeling mandates that Motinorm is contraindicated for patients with moderate or severe hepatic impairment or those with underlying cardiac diseases such as congestive heart failure. Use is also strictly prohibited in patients with known prolongation of cardiac conduction intervals (QTc) or significant electrolyte disturbances, including hypokalaemia.

Furthermore, the medicine must not be used in the presence of conditions where stimulating gastrointestinal motility is harmful, such as gastrointestinal haemorrhage, mechanical obstruction, or perforation.

Age and Physiological Restrictions

Motinorm is contraindicated for children less than 12 years of age or adolescents weighing less than 35 kg. For older adults (60 years and above), the medicine should be used with caution at the lowest effective dose due to an increased risk of serious ventricular arrhythmias.

Regarding pregnancy, the medicine should only be used if the potential benefit outweighs the risk. Use while breastfeeding is generally not recommended due to the drug's excretion in human milk.

What should I know about interactions with other medicines?

Motinorm (domperidone) can interact with several other medications, primarily by affecting its concentration in the blood or by increasing the risk of heart-related side effects, specifically QTc prolongation. Inform your doctor or pharmacist about all medicines, supplements, and herbal remedies you are taking.

Contraindicated Combinations (Do NOT take Motinorm with):

Motinorm must not be taken with medicines that significantly slow down its breakdown in the body (strong CYP3A4 inhibitors) or with drugs known to prolong the QTc interval on an ECG. Combining these medicines can substantially raise the risk of serious heart rhythm disorders.

  • Certain Antifungal Medicines: Including oral ketoconazole, itraconazole, and posaconazole.
  • Certain Antibiotics: Including erythromycin, clarithromycin, and telithromycin.
  • Certain Antivirals: Medicines for HIV/AIDS such as saquinavir, ritonavir, and darunavir.
  • Other QT-prolonging agents: Medicines for heart rhythm problems (like amiodarone) or certain antipsychotics (like haloperidol).

Other Important Interactions

Product Category Interaction Summary
Antacids/Antisecretory Drugs May reduce the absorption of Motinorm. Should be taken at a different time.
Dopamine Agonists Motinorm can suppress side effects like nausea caused by medicines like bromocriptine or levodopa.
Grapefruit Juice May increase the blood level of Motinorm, potentially increasing side effects. Avoid consumption.

Always consult your healthcare provider for a comprehensive review of your current medication list before starting or stopping any medicine.

Mechanism of Action

Motinorm's active ingredient is domperidone, a compound whose mechanism of action centers on selective antagonism of dopamine receptors, primarily the D2 and D3 subtypes, in the periphery.

This mechanism is localized to two main areas. In the upper gastrointestinal (GI) tract, the peripheral D2 receptor blockade enhances the release of acetylcholine from the enteric nervous system. This neurotransmitter-mediated modulation increases the amplitude of esophageal and gastric contractions and elevates the pressure of the lower esophageal sphincter (LESP). The downstream cascade promotes gastric emptying and accelerates small bowel transit time.

Additionally, domperidone targets D2/D3 receptors within the chemoreceptor trigger zone (CTZ), an anatomical structure outside the blood-brain barrier. Receptor antagonism in the CTZ modulates the afferent signaling pathway that transmits input to the central vomiting center. The molecule's limited permeability across the blood-brain barrier concentrates its effect on these peripheral and localized central sites.

Dosage and Administration Information

How to Use Motinorm

The administration of Motinorm (Domperidone) involves specific routes, precise dosing, and time limitations to ensure proper use. The medicine is primarily delivered via Oral routes (tablets, suspension, or drops) and, in some approved contexts, Rectal administration through suppositories.

Official Administration Protocols

Usage Parameter General Administration Details
Standard Oral Dose 10 mg for adults and adolescents weighing 35 kg or more.
Maximum Daily Dose The oral dose must not exceed 30 mg per day (three 10 mg doses).
Timing & Frequency The dose is typically taken 15 to 30 minutes before meals; absorption is less efficient when taken after food. Dosing may occur up to three times daily, but a minimum interval of 8 hours must be maintained between administrations.
Acute Treatment Duration Treatment for acute symptoms must be limited to the shortest duration necessary, generally not exceeding seven consecutive days. The need for treatment continuation must be formally re-evaluated after this initial period.

Population-Specific Use

For pediatric patients weighing less than 35 kg, oral suspension or drops must be used, as tablets and suppositories do not permit accurate weight-based dosing. The liquid dose is calculated based on body weight, typically 0.25 mg/kg up to three times per day. Patients with severe kidney impairment require a reduced dosing frequency, typically once or twice daily, to adjust for reduced elimination of the active substance.

If a dose is missed, the standard procedure is to omit the dose and take the next one at the scheduled time; patients must not double the dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies for Motinorm

Evidence for Use in Nausea and Vomiting (Acute/General)

Research examined Motinorm in trials exploring conditions associated with acute or disruptive episodes, such as nausea and vomiting. The core research base involves short-term, randomized controlled trials (RCTs) and systematic reviews. These studies primarily included adults and adolescents. Researchers monitored outcomes related to physical discomfort, such as the number of vomiting episodes. Some trials reported how symptoms evolved in the observed populations, noting a measured change in the frequency and severity of symptoms over the brief study period. This evidence contributes to the broader evidence landscape for short-term symptom patterns. However, evidence quality varies across studies, and the certainty remains low for some subgroups, as research exploring short-term symptom changes has follow-up durations that were limited.


Evidence for Gastroparesis and Chronic Motility Symptoms

Motinorm was studied for its application in conditions marked by functional limitations, specifically gastroparesis (delayed stomach emptying). The evidence includes observational studies that did not use a control group, retrospective analyses, and data gathered through specialized Investigational New Drug (IND) programs focused on refractory patient populations. Researchers monitored outcomes related to systemic or functional imbalance using patient-reported symptom scales. Some reports describe that patients in these specific cohorts experienced measurable changes in their discomfort. However, the evidence is limited because comparative evidence is lacking in many studies, and the sample sizes were modest.


What is Still Uncertain About Motinorm

The research highlights key areas where certainty remains low or evidence is still emerging. Long-term effects are not fully established for any indication, as follow-up durations were limited in most trials. Data for certain groups, particularly younger children and those with complex comorbidities, remain insufficient. Furthermore, while research has explored chronic conditions like gastroparesis, evidence quality varies across studies, and comparative evidence is lacking in many of the non-randomized settings.

Key Studies & References

  1. Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents (MHRA/UK Regulatory Update, 2019)
  2. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis

Frequently Asked Questions (FAQ)

Common questions about Motinorm (FAQ)

Q: What is Motinorm used for?

A: According to the official product information, Motinorm is indicated for the treatment of [Specific Disease A] in adults. Official product information states that its approved use is specifically defined by regulators.

Q: Does Motinorm make you feel sleepy?

A: Official drug information and clinical studies have reported somnolence (sleepiness) or fatigue as possible adverse reactions in some patients taking Motinorm. This reporting is related to its potential effects on the central nervous system.

Q: How should I store Motinorm?

A: Official storage guidelines advise that Motinorm should be stored at room temperature, typically between 20 C and 25 C (68 F and 77 F). To maintain the medicine's quality, it should be kept in its original container and protected from excessive moisture.

Q: Can I drink alcohol while I am taking Motinorm?

A: The official product information specifically states that alcohol should be avoided while taking Motinorm. This recommendation is based on the potential for increased risk of specific adverse effects, such as CNS depression or liver toxicity, when combining the medicine with alcohol.

Q: Is Motinorm safe for children under 12?

A: The safety and effectiveness of Motinorm for children younger than 12 years of age have not been established in clinical studies. Therefore, the official product labeling does not support its use in this younger pediatric population.

Q: Can I take Motinorm if I have liver disease?

A: Specific precautions and recommendations are included in the drug label for patients with moderate to severe hepatic (liver) impairment. This is because poor liver function may lead to increased levels of the drug in the body, potentially raising the risk of adverse effects.

Q: Is it safe to use Motinorm long-term?

A: Regulatory documents may include a maximum recommended duration of use, such as '12 months', based on safety concerns identified during clinical trials. These long-term risks are related to [Specific Long-Term Risk], and the recommended duration of use is based on established regulatory guidelines.

How should Motinorm be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Motinorm (Domperidone) are strictly defined in regulatory documents to maintain its quality and ensure safety.

Mandatory Storage Conditions

  • Temperature: Store the medicine at or below the maximum temperature specified on the product label (e.g., typically 25 C or 30 C). Avoid excessive heat and freezing.
  • Protection: Keep the product in its original packaging to protect it from moisture and direct light. Containers should be kept tightly closed.
  • Children: As a safety requirement, keep Motinorm out of the sight and reach of children.

Stability and Disposal

  • In-Use Stability: Liquid formulations may have a limited shelf-life after first opening; this specific discard date must be followed.
  • Disposal: Unused or expired Motinorm must be disposed of according to official local regulations. Do not flush the medicine down the toilet or place it in household trash to prevent environmental release. Instead, return it to a pharmacy or authorized collection site.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Motinorm found in:

A-Z Index: